These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 25286744)

  • 1. The effect of induction of CYP3A4 by St John's wort on ambrisentan plasma pharmacokinetics in volunteers of known CYP2C19 genotype.
    Markert C; Kastner IM; Hellwig R; Kalafut P; Schweizer Y; Hoffmann MM; Burhenne J; Weiss J; Mikus G; Haefeli WE
    Basic Clin Pharmacol Toxicol; 2015 May; 116(5):423-8. PubMed ID: 25286744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction of ambrisentan with clarithromycin and its modulation by polymorphic SLCO1B1.
    Markert C; Hellwig R; Burhenne J; Hoffmann MM; Weiss J; Mikus G; Haefeli WE
    Eur J Clin Pharmacol; 2013 Oct; 69(10):1785-93. PubMed ID: 23748747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-dependent induction of CYP3A activity by St. John's wort alone and in combination with rifampin.
    Hohmann N; Friedrichs AS; Burhenne J; Blank A; Mikus G; Haefeli WE
    Clin Transl Sci; 2024 Aug; 17(8):e70007. PubMed ID: 39152679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity.
    Wang Z; Gorski JC; Hamman MA; Huang SM; Lesko LJ; Hall SD
    Clin Pharmacol Ther; 2001 Oct; 70(4):317-26. PubMed ID: 11673747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The extent of induction of CYP3A by St. John's wort varies among products and is linked to hyperforin dose.
    Mueller SC; Majcher-Peszynska J; Uehleke B; Klammt S; Mundkowski RG; Miekisch W; Sievers H; Bauer S; Frank B; Kundt G; Drewelow B
    Eur J Clin Pharmacol; 2006 Jan; 62(1):29-36. PubMed ID: 16341856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of the CYP3A inhibitor ketoconazole on the PXR-mediated induction of CYP3A activity.
    Fuchs I; Hafner-Blumenstiel V; Markert C; Burhenne J; Weiss J; Haefeli WE; Mikus G
    Eur J Clin Pharmacol; 2013 Mar; 69(3):507-13. PubMed ID: 22968811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of St. John's wort on the steady-state pharmacokinetics and metabolism of bosentan.
    Markert C; Ngui P; Hellwig R; Wirsching T; Kastner IM; Riedel KD; Burhenne J; Weiss J; Mikus G; Haefeli WE
    Int J Clin Pharmacol Ther; 2014 Apr; 52(4):328-36. PubMed ID: 24472406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No clinically relevant CYP3A induction after St. John's wort with low hyperforin content in healthy volunteers.
    Mueller SC; Majcher-Peszynska J; Mundkowski RG; Uehleke B; Klammt S; Sievers H; Lehnfeld R; Frank B; Thurow K; Kundt G; Drewelow B
    Eur J Clin Pharmacol; 2009 Jan; 65(1):81-7. PubMed ID: 18762932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. St John's wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole.
    Wang LS; Zhou G; Zhu B; Wu J; Wang JG; Abd El-Aty AM; Li T; Liu J; Yang TL; Wang D; Zhong XY; Zhou HH
    Clin Pharmacol Ther; 2004 Mar; 75(3):191-7. PubMed ID: 15001970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of simultaneous induction and inhibition of CYP3A by St John's Wort and ritonavir on CYP3A activity.
    Hafner V; Jäger M; Matthée AK; Ding R; Burhenne J; Haefeli WE; Mikus G
    Clin Pharmacol Ther; 2010 Feb; 87(2):191-6. PubMed ID: 19924124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The recovery time-course of CYP3A after induction by St John's wort administration.
    Imai H; Kotegawa T; Tsutsumi K; Morimoto T; Eshima N; Nakano S; Ohashi K
    Br J Clin Pharmacol; 2008 May; 65(5):701-7. PubMed ID: 18294328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of St John's Wort on CYP2C19 activity with respect to genotype.
    Wang LS; Zhu B; Abd El-Aty AM; Zhou G; Li Z; Wu J; Chen GL; Liu J; Tang ZR; An W; Li Q; Wang D; Zhou HH
    J Clin Pharmacol; 2004 Jun; 44(6):577-81. PubMed ID: 15145964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of rifampicin (rifampin) on the pharmacokinetics and safety of ambrisentan in healthy subjects: a single-sequence, open-label study.
    Harrison B; Magee MH; Mandagere A; Walker G; Dufton C; Henderson LS; Boinpally R
    Clin Drug Investig; 2010; 30(12):875-885. PubMed ID: 20923245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physiologically Based Pharmacokinetic Modelling of Hyperforin to Predict Drug Interactions with St John's Wort.
    Adiwidjaja J; Boddy AV; McLachlan AJ
    Clin Pharmacokinet; 2019 Jul; 58(7):911-926. PubMed ID: 30675694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects.
    Dresser GK; Schwarz UI; Wilkinson GR; Kim RB
    Clin Pharmacol Ther; 2003 Jan; 73(1):41-50. PubMed ID: 12545142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relevance of in vitro and clinical data for predicting CYP3A4-mediated herb-drug interactions in cancer patients.
    Goey AK; Mooiman KD; Beijnen JH; Schellens JH; Meijerman I
    Cancer Treat Rev; 2013 Nov; 39(7):773-83. PubMed ID: 23394826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The interaction between St John's wort and an oral contraceptive.
    Hall SD; Wang Z; Huang SM; Hamman MA; Vasavada N; Adigun AQ; Hilligoss JK; Miller M; Gorski JC
    Clin Pharmacol Ther; 2003 Dec; 74(6):525-35. PubMed ID: 14663455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme.
    Markowitz JS; Donovan JL; DeVane CL; Taylor RM; Ruan Y; Wang JS; Chavin KD
    JAMA; 2003 Sep; 290(11):1500-4. PubMed ID: 13129991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opposite effects of short-term and long-term St John's wort intake on voriconazole pharmacokinetics.
    Rengelshausen J; Banfield M; Riedel KD; Burhenne J; Weiss J; Thomsen T; Walter-Sack I; Haefeli WE; Mikus G
    Clin Pharmacol Ther; 2005 Jul; 78(1):25-33. PubMed ID: 16003289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rivaroxaban and macitentan can be coadministered without dose adjustment but the combination of rivaroxaban and St John's wort should be avoided.
    Huppertz A; Werntz L; Meid AD; Foerster KI; Burhenne J; Czock D; Mikus G; Haefeli WE
    Br J Clin Pharmacol; 2018 Dec; 84(12):2903-2913. PubMed ID: 30192025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.